Recently Kim et al. utilized next-generation RNAi therapeutics to demonstrate that exosomes, by leveraging their inherent strengths, can effectively deliver siRNA to target oncogenic drivers such as KRAS mutations, modulate angiogenesis through the silencing of Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2), and counteract chemoresistance by disrupting metabolic pathways, thereby providing a personalized and efficient approach to cancer treatment [163]. This evidence concerns the gene KDR and cancer.